Cited 0 times in Scipus Cited Count

Multicenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia

DC Field Value Language
dc.contributor.authorPark, S-
dc.contributor.authorYoon, SS-
dc.contributor.authorLee, JH-
dc.contributor.authorPark, JS-
dc.contributor.authorJang, JH-
dc.contributor.authorLee, JW-
dc.date.accessioned2018-05-04T00:25:43Z-
dc.date.available2018-05-04T00:25:43Z-
dc.date.issued2016-
dc.identifier.issn0925-5710-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/15044-
dc.description.abstractMulticenter, prospective study was conducted to evaluate the efficacy of biweekly romiplostim in maintaining platelet >/= 30 x 10(9)/L for at least 4 weeks. Treatment was started with a weekly injection (1 mcg/kg), and the dose was escalated until a titrated dose was achieved that maintained a platelet 50-200 x 10(9)/L for four consecutive weeks. Patients were scheduled to a biweekly schedule, and returned to a weekly schedule if platelets fell to <30 x 10(9)/L. Eighteen patients were enrolled (median platelet, 14 x 10(9)/L). After the first weekly schedule, ten of eighteen (55.6 %) attained a median titrated dose of 3 mcg/kg and proceeded to the first biweekly schedule. However, all failed to maintain a platelet >/= 30 x 10(9)/L for at least 4 weeks, and returned to a second weekly schedule, where eight of the ten achieved a titrated dose (median, 5 mcg/kg) and moved to a second schedule of biweekly romiplostim. Three of the eight (37.5 %) showed platelet >/= 30 x 10(9)/L for 4, 8, and 10 weeks, but all eight patients eventually experienced a drop in platelets. Lengthening the dose interval of romiplostim to greater than a week is not feasible to maintain stable platelet count.-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHDrug Administration Schedule-
dc.subject.MESHFemale-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPlatelet Count-
dc.subject.MESHProspective Studies-
dc.subject.MESHReceptors, Fc-
dc.subject.MESHRecombinant Fusion Proteins-
dc.subject.MESHThrombocytopenia-
dc.subject.MESHThrombopoietin-
dc.subject.MESHTime Factors-
dc.subject.MESHTreatment Outcome-
dc.titleMulticenter, prospective study to evaluate the efficacy of biweekly romiplostim administration in patients with immune thrombocytopenia-
dc.typeArticle-
dc.identifier.pmid26511480-
dc.contributor.affiliatedAuthor박, 준성-
dc.type.localJournal Papers-
dc.identifier.doi10.1007/s12185-015-1889-7-
dc.citation.titleInternational journal of hematology-
dc.citation.volume103-
dc.citation.number1-
dc.citation.date2016-
dc.citation.startPage44-
dc.citation.endPage52-
dc.identifier.bibliographicCitationInternational journal of hematology, 103(1). : 44-52, 2016-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1865-3774-
dc.relation.journalidJ009255710-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
There are no files associated with this item.

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse